alemtuzumab

Documents about alemtuzumab

• Infections Associated With the Use of Alemtuzumab#828224ClinicalTrials.gov
• Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects#1212064ClinicalTrials.gov
• The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias#849568ClinicalTrials.gov
• Alemtuzumab and Pentostatin In T-cell Neoplasms#810935ClinicalTrials.gov
• Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)#1085448ClinicalTrials.gov
• Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine#1124737ClinicalTrials.gov
• Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia#1088022ClinicalTrials.gov
• CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma#1008950ClinicalTrials.gov
• Alemtuzumab Induction in Islet Transplantation#353435ClinicalTrials.gov
• R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia#1111509ClinicalTrials.gov
• Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)#884690ClinicalTrials.gov
• Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia#1363048ClinicalTrials.gov
• Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia#1363694ClinicalTrials.gov
• The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients#1418611ClinicalTrials.gov
• Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab#1058200ClinicalTrials.gov
• Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia#835510ClinicalTrials.gov
• Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis#807618ClinicalTrials.gov
• Alemtuzumab to Treat Sporadic Inclusion Body Myositis#1381780ClinicalTrials.gov
• Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease#900497ClinicalTrials.gov
• Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia#863121ClinicalTrials.gov
• Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab#1182885ClinicalTrials.gov
• Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients#893487ClinicalTrials.gov
• TMLI and Alemtuzumab for Treatment of Sickle Cell Disease#1310396ClinicalTrials.gov
• Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).#895870ClinicalTrials.gov
• Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients#1182586ClinicalTrials.gov
• HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab#1408265ClinicalTrials.gov
• Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia#868639ClinicalTrials.gov
• Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis#880990ClinicalTrials.gov
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One#1104324ClinicalTrials.gov
• Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis#1321167ClinicalTrials.gov
• Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL#871579ClinicalTrials.gov
• Alemtuzumab for ANCA Associated Refractory Vasculitis#1010953ClinicalTrials.gov
• Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia#238114ClinicalTrials.gov
• Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)#885902ClinicalTrials.gov
• Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure#1163710ClinicalTrials.gov
• Alemtuzumab and CHOP in T-cell Lymphoma#1410280ClinicalTrials.gov
• Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia#1418976ClinicalTrials.gov
• The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL#813665ClinicalTrials.gov
• Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation#813404ClinicalTrials.gov
• Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia#1112854ClinicalTrials.gov
• Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas#836618ClinicalTrials.gov
• Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy#1338369ClinicalTrials.gov
• Safety and Efficacy of Campath in Nonmyeloablative Transplantation#1370279ClinicalTrials.gov
• Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients#805364ClinicalTrials.gov
• Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia#906662ClinicalTrials.gov
• Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma#1093541ClinicalTrials.gov
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT#1260314ClinicalTrials.gov
• A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion#840882ClinicalTrials.gov
• Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma#878476ClinicalTrials.gov
• The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)#886724ClinicalTrials.gov